Skip to main content
editorial
. 2019 Jul 9;8(4):221–238. doi: 10.1159/000501501

Table 5.

Clinical trials of IO as adjuvant or neoadjuvant after resection/RFA

Phase Target Agent Company Trial No.
3 PD-1 Nivolumab (adjuvant, name: CheckMate 9DX) BMS NCT03383458
3 PD-L1 ± VEGFR2 Duravalumab ± bevacizumab (adjuvant, name: EMERALD-2) AstraZeneca NCT03847428
2 PD-1 Nivolumab (adjuvant, name: NIVOLVE) Kindai Univ. (JP) UMIN000026648
2 PD-1 + CTLA-4 Nivolumab + ipilimumab (neoadjuvant + adjuvant) MD Anderson CC NCT03222076
1 PD-1 + MET/VEGFR2 Nivolumab + cabozantinib (neoadjuvant) Sidnet Kimmel C-CC NCT03299464